Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0006142 (
breast cancer
)
160,383
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effects of motorcycle exhaust particulate (MEP) on cytochrome P-450-dependent monooxygenases were determined using MCF-7 human
breast cancer
cells treated with organic extracts of MEP. Treatment with MEP extract produced concentration- and time-dependent increases of monooxygenase activity in S9 fractions. Treatment with 50 microg/ml MEP extract for 24 h increased benzo[a]pyrene hydroxylase and 7-ethoxycoumarin, 7-ethoxyresorufin, and methoxyresorufin O-dealkylases activities in S9. Treatments with 1 and 10 microg/ml MEP extract for 24 h markedly enhanced catabolism of 17beta-estradiol in MCF-7 cells. Cotreatment of the cells with 2 microM alpha-naphthoflavone, a cytochrome P-450 inhibitor and arylhydrocarbon receptor antagonist, blocked the increase of benzo[a]pyrene hydroxylase activity induced by treatment with MEP extract alone. Immunoblot analyses of S9 proteins using a mouse monoclonal antibody 1-12-3 against rat cytochrome P-450 1A1 and a rabbit polyclonal antibody against human cytochrome P-450 1B1 revealed that MEP extract induced proteins immunorelated to cytochromes P-450 1A1 and 1B1. RNA blot analysis of total RNA using human cytochrome P-450 (CYP)1A1 3'-end and human
CYP1B1
RT-PCR product cDNA probes showed that MEP extract increased the levels of cytochromes P-450 1A1 and 1B1 mRNA hybridizable to the respective cDNA probes. Treatment with 10 micro M benzo[a]pyrene, a component of MEP extract, for 24 h induced catalytic activity, protein, and mRNA of cytochromes P-450 1A1 and 1B1 in MCF-7 cells. Treatment with MEP extract increased cytochromes P-450 1A1 and 1B1 proteins and mRNA levels in NCI-H322 human lung carcinoma and CL5 human lung adenocarcinoma cells. The extract also increased cytochrome P-450 1A1, but not cytochrome P-450 1B1, protein, and mRNA, in HepG2 human hepatoma cells. The present findings demonstrate that MEP extract has the ability to induce cytochromes P-450 1A1 and 1B1 in the estrogen-responsive MCF-7 cells. Induction of the carcinogen- and estrogen-metabolizing cytochromes P-450 1A1 and 1B1 may be an important factor to consider in assessing the potential health effects associated with human exposure to MEP.
...
PMID:Induction of cytochromes P-450 1A1 and 1B1 by motorcycle exhaust particulate in human breast cancer MCF-7 cells. 1239 73
Epidemiological studies indicate that most risk factors for
breast cancer
are related to reproductive and hormonal factors. Estrogen has been proposed to trigger
breast cancer
development via an initiating mechanism involving its metabolite, catechol estrogen (CE). Because of the important role of cytochrome P450 1B1 (
CYP1B1
) and catechol O-methyltransferase ( COMT) in mammary estrogen and carcinogen metabolism, we examined the
CYP1B1
and COMT genes to determine whether genetic variations could account for inter-individual differences in
breast cancer
. In this case-control study, we determined
CYP1B1
and COMT genotypes in 84
breast cancer
patients and 103 healthy unrelated women controls from a Turkish population. In the case of
CYP1B1
, we genotyped CYP1B1*3 (L432 V) allele. We found that carriers of the CYP1B1*3 allele were more frequent among
breast cancer
patients with adjusted odds ratio (OR) for age, age at menarche, age at first full-term pregnancy, body mass index (BMI) and smoking status of 2.32 (95% confidence interval 1.26-4.25) associated with the allele. However, this allele appeared to be a significant factor for susceptibility only in patients with a BMI greater than 24 kg/m(2). Menopausal status did not appear to affect susceptibility. In the case of COMT, there was no significant difference in susceptibility for
breast cancer
development between patients with low activity COMT-L (V158 M) allele and high activity COMT-H allele, and susceptibility was not affected by menopausal status, BMI or
CYP1B1
genotype. We conclude that the CYP1B1* 3 allele appears to be a factor for susceptibility to
breast cancer
in Turkish women especially those with a BMI greater than 24 kg/m(2).
...
PMID:Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. 1241 27
Breast cancer
is the most prevalent cancer among women in Western countries, and its prevalence is also increasing in Asia. The major risk factor for
breast cancer
can be traced to reproductive events that influence the lifetime levels of hormones. However, a large percentage of
breast cancer
cases cannot, be explained by these risk factors. The identification of susceptibility factors that predispose individuals to
breast cancer
(for instance, if they are exposed to particular environmental agents) could possibly give further insight into the etiology of this malignancy and provide targets for the future development of therapeutics. The most interesting candidate genes include those that mediate a range of functions. These include carcinogen metabolism, DNA repair, steroid hormone metabolism, signal transduction, and cell cycle control. we conducted a hospital-based case-control study on South Korea to evaluate the potential modifying role of the genetic pollymprphisms of selected low penetrance gens that are involved carcinogen metabolisms (i.e., CYP1A1, CYP2E1, GSTM1/T1/P1, NAT1/2, etc.), estrogen synthesis and metabolism (i.e., CYP19, CYP17,
CYP1B1
, COMT, ER-alpha, etc.), DNA repair (i.e., XRCC1/3, ERCC2/4, ATM, AGT, etc.), and signal transduction as well as others (i.e., TGF- beta, IGF-1, TNF- beta, IL-1B, IL-1RN, etc.). We also took into account the potential interaction between these and the known risk factors of
breast cancer
. The results of selected genes will be presented in this mini-review.
...
PMID:Genetic polymorphisms and cancer susceptibility of breast cancer in Korean women. 1254 72
Mammographic density has been linked with exposure to endogenous and exogenous steroid hormones, and increased
breast cancer
risk. Variation in breast density may be due, in part, to polymorphisms in steroid hormone biosynthesis, metabolism and signaling genes. We conducted cross-sectional analyses within the Nurses' Health Study (n = 538), to investigate variation in mammographic breast density, by 10 polymorphisms in eight candidate genes (CYP17, CYP19, CYP1A1,
CYP1B1
, COMT, UGT1A1, AR, and AIB1). Breast density was assessed using a computer-assisted technique. We evaluated whether associations between variant alleles of these genes and breast density differed by menopause and postmenopausal hormone (PMH) use. Polymorphisms in CYP17, CYP19,
CYP1B1
, COMT CYP1A1, or AR were not associated consistently with breast density among premenopausal or postmenopausal women. Premenopausal women with the 7/7 UGT1A1 genotype had lower breast density (difference compared to the 6/6 genotype of: -16.5% density; p = 0.04). In contrast, postmenopausal women with the 7/7 UGT1A1 genotype had greater breast density compared to those with the 6/6 genotype (+6.2% density; p = 0.05); this association was strongest among current PMH users (+13.0% density; p = 0.03). In analyses limited to postmenopausal women, breast density was also greater among women carrying short AIB1 alleles (< or = 26 glutamine repeats; +4.1% density; p = 0.04). Most of the variants in the candidate
breast cancer
genes evaluated in this study are not strong predictors of breast density. However, our findings of differences in associations for UGT1A1 and AIB1 genotypes with breast density by menopausal status needs additional corroboration.
Breast Cancer
Res Treat 2003 Jan
PMID:Polymorphisms in steroid hormone pathway genes and mammographic density. 1260 2
A candidate antitumor agent, 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F-203), was empirically discovered through the National Cancer Institute's Anticancer Drug Screen from a unique growth inhibitory-response profile, indicating a novel mechanism of action. 5F-203 activates the CYP1 family of cytochrome P450, involving aryl hydrocarbon receptor translocation into the nucleus. To characterize more completely the pathways involved in 5F-203 toxicity, cDNA microarrays were used to determine gene expression changes in MCF-7, a 5F-203-sensitive
breast cancer
cell line, after treatment with 1 microM 5F-203. The mRNA expression of CYP1A1 and
CYP1B1
were both increased approximately 20-fold after 24 h, but less after 6 h of treatment, confirming previous results. However, the most pronounced drug-induced change was in the PLAB gene, encoding one of the bone morphogenic proteins in the transforming growth factor-beta (TGF-beta) superfamily. Other induced gene expressions included the apoptosis-initiating receptor TNFRSF6 (CD95/FAS), the DNA-damage response genes CDKN1A (p21/Cip1), p53-induced gene-3, and DNA binding protein 2. In contrast, the transcription factor c-Myc showed reduced expression. Western blot analysis also showed induction of p53 protein expression in response to 5F-203 treatment. In contrast to the MCF-7 data, MDA-MB-435, a cancer cell line resistant to 5F-203, showed no change in expression of any of these genes or the p53 protein under the same conditions of 5F-203 treatment. These data are consistent with the idea that CYP1A1 and
CYP1B1
activation leads to 5F-203 toxicity through DNA damage-induced apoptosis, as well as signaling through a variant member of the TGF-beta superfamily.
...
PMID:Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. 1260 87
A case-control study was performed to assess the potential influence of CYP19 Arg(264)Cys and
CYP1B1
Leu(432)Val polymorphisms on
breast cancer
risk in a series of Korean
breast cancer
patients and controls. The results suggest that the CYP19 Arg(264)Cys polymorphism modifies
breast cancer
risk (OR=1.5, 95% CI=1.1-2.2), especially in association with alcohol consumption (P for interaction=0.04), whereas the
CYP1B1
Leu(432)Val polymorphism appears to play no role here.
...
PMID:Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women. 1261 73
Breast development, one of the first signs of puberty, is closely associated with age at menarche; and early menarche is in turn a well-established risk factor for female
breast cancer
. We examined the relationships between the onset of puberty and gene variants for certain enzymes that regulate hormone metabolism among 137 healthy nine-year-old girls from two pediatric clinics. High-activity CYP17 alleles, involved in estrogen formation, and high-activity CYP1A2 and
CYP1B1
alleles, whose gene products metabolize estradiol, were not associated with pubertal stage. High activity CYP3A4, but not CYP3A5, which primarily metabolizes testosterone, showed a striking association with the onset of puberty (adjusted odds ratio, 3.21; 95% confidence interval, 1.62-6.89 for the genotype 0-1-2 rapid alleles). Of the homozygous CYP3A4*1B/1B girls, 90% had reached puberty; whereas, for the low-activity homozygous CYP3A4*1A/1A individuals, only 40% had done so. In heterozygotes, 56% had reached puberty.
CYP1B1
, CYP3A4, and CYP3A5 rapid variants were more common in African-American than in Hispanic or Caucasian girls.
...
PMID:The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. 1269 7
The effect of airborne frying-meat emission particulate (FMEP) on metabolism of 17beta-estradiol (E(2)) to potentially toxic catechol estrogens 2- and 4-hydroxyestradiol (2- and 4-OH-E(2)) was determined using human lung adenocarcinoma CL5 cells treated with organic extracts of beef FMEP. E(2) was incubated with microsomes prepared from untreated CL5 cells or cells treated with 200 microg/ml FMEP extract for 6 h. E(2) metabolites formed were analyzed by high-performance liquid chromatography (HPLC). The results revealed that treatment with FMEP produced three-and twofold increases of 2- and 4-hydroxylation of E(2), respectively. Monooxygenase activity and immunoblot analyses showed that FMEP markedly induced microsomal 7-ethoxyresorufin O-deethylase (EROD) activity and cytochrome P-450 (CYP) IAI and CYPIBI protein levels. Similar increases in E(2) hydroxylation, EROD activity, and CYP protein levels were observed with HepG2 human hepatoma and MCF-7 human
breast cancer
cells treated with FMEP or 1 microM dibenz[a,h]anthracene. Cotreatment of CL5 cells with FMEP extract and 2 microM alpha-naphthoflavone, an arylhydrocarbon receptor antagonist, blocked the inductive effects of FMEP on E(2) hydroxylation and EROD activity. Additions of 0.01, 0.1, or 1 microM alpha-naphthoflavone, a CYP inhibitor, to microsomes produced concentration-dependent decreases in E(2) 2-hydroxylation and EROD activity of CL5 cells induced by dibenz[a,h]anthracene. The present finding demonstrates that FMEP can increase formation of 2-OH-E(2) and 4-OH-E(2) by human lung cells, and induction of CYP1A1 and
CYP1B1
is a potential mechanism underlying increased E(2) metabolism. The toxicological significance of FMEP and estrogen interaction warrants further investigation.
...
PMID:Effect of frying-meat emission particulate on 17beta-estradiol 2- and 4-hydroxylation in human lung adenocarcinoma CL5 cells. 1279 42
The major known risk factors for female
breast cancer
are associated with prolonged exposure to increased levels of oestrogen. The predominant theory relates to effects of oestrogen on cell growth. Enhanced cell proliferation, induced either by endogenous or exogenous oestrogens, increases the number of cell divisions and thereby the possibility for mutation. However, current evidence also supports a role for oxidative metabolites, in particular catechol oestrogens, in the initiation of
breast cancer
. As observed in drug and chemical metabolism, there is considerable interindividual variability (polymorphism) in the conjugation pathways of both oestrogen and catechol oestrogens. These person-to-person differences, which are attributed to polymorphisms in the genes encoding for the respective enzymes, might define subpopulations of women with higher lifetime exposure to hormone-dependent growth promotion, or to cellular damage from particular oestrogens and/or oestrogen metabolites. Such variation could explain a portion of the cancer susceptibility associated with reproductive effects and hormone exposure. In this paper the potential role of polymorphic genes encoding for enzymes involved in oestrogen biosynthesis (CYP17, CYP19, and 17beta-HSD) and conversion of the oestrogen metabolites and their by-products (COMT, CYP1A1,
CYP1B1
, GSTM1, GSTM3, GSTP1, GSTT1 and MnSOD) in modulating individual susceptibility to
breast cancer
are reviewed. Although some of these low-penetrance genes appeared as good candidates for risk factors in the etiology of sporadic
breast cancer
, better designed and considerably larger studies than the majority of the studies conducted so far are evidently needed before any firm conclusions can be drawn.
...
PMID:Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. 1288 6
Epidemiological studies indicate that Asian women have a lower
breast cancer
incidence compared with their counterparts in the West, and the difference has been related to soya consumption. Animal studies have suggested that soya may prevent dimethylbenz[a]anthracene (DMBA)-induced carcinogenesis in the breast. In the present study a cell culture model was developed to address the effect of soya isoflavones on the DMBA-induced DNA damage. DMBA is metabolized into a DNA-attacking moiety by two phase I cytochrome P450 (CYP) enzymes CYP1A1 and
CYP1B1
. DNA mutation caused by this genotoxic agent is a crucial step in cancer initiation. Substances that interfere with the CYP1 enzyme activities can affect the initiation. In the present study, genistein was found to be an effective inhibitor of recombinant human CYP1A1 and
CYP1B1
with Ki of 15.35 and 0.68 micromol/l. The other soya isoflavone daidzein, on the other hand, did not demonstrate any significant inhibition of the enzyme activities. At the transcriptional level, DMBA induced the CYP1 enzyme expressions by stimulating the xenobiotic response element (XRE)-dependent transactivation pathway. When genistein (25 micromol/l) was co-administered with DMBA, the XRE-Luc activity the CYP1 mRNA abundances were significantly suppressed. The present study illustrated that the soya isoflavone genistein, but not daidzein, protected against DMBA genotoxicity.
...
PMID:A potential protective mechanism of soya isoflavones against 7,12-dimethylbenz[a]anthracene tumour initiation. 1290 8
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>